Search results
Results From The WOW.Com Content Network
Number of employees. 354. Website. sangamo .com. Footnotes / references. [1] President and CEO Sandy Macrae in 2018. Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
Sangamo Therapeutics (NASDAQ:SGMO) stock was on the up and up to kick off the week as the business revealed that it has made some key forward progress in its gene therapy that is designed to treat ...
A bevy of Sangamo Therapeutics news for Tuesday has SGMO stock flying high today.Source: Shutterstock Sangamo Therapeutics (NASDAQ:SGMO) starts off the day by announcing a new deal to increase its ...
Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease. As ...
Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
S. Sangamo Therapeutics. Categories: Biotechnology companies established in the 20th century. Technology companies established in 1995. Biotechnology companies by year of establishment. 1995 in biotechnology.
Amgen Inc. Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total. [5] The name "AMGen" is a portmanteau of the ...
Investors got more disappointing news regarding Sangamo Therapeutics' gene-editing approach this week.